New service for orphan drug development
Questions will be handled by the relevant expert, who will first assess whether the question can be answered without obtaining further information, and within a reasonable time-frame, and will subsequently provide a written answer.
“We often come across companies who are thinking of developing their drug according to the Orphan Drug legislation, but are unsure of some of the fundamentals they need to know to get them started,” said Dr Anthony Hall, Chief Medical Officer, PSR.
“OrphanIQ provides such companies an easy and accessible way of gaining insight into this highly specialised area of Drug Development. Even when the development process is already underway, companies often have short but important questions relating, for example, to their clinical plan or to reimbursement issues.”
Website: www.orphan-IQ.com
